Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 12/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.97 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.97 |
| ▸ | PRCP | P42785 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12648367 | 1.00 | SIGMAR1 (1.00) | SIGMAR1MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL30687922 | 1.00 | SIGMAR1 (1.00) | SIGMAR1MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL7094797 | 0.88 | SIGMAR1 (0.78) | SIGMAR1MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL9047802 | 0.86 | SIGMAR1 (0.76) | SIGMAR1MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL9048214 | 0.83 | SIGMAR1 (0.70) | SIGMAR1MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL9050714 | 0.81 | SIGMAR1 (0.67) | SIGMAR1MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL9046003 | 0.80 | SIGMAR1 (0.66) | SIGMAR1MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL9049352 | 0.80 | SIGMAR1 (0.66) | SIGMAR1MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL7698474 | 0.78 | SIGMAR1 (0.62) | SIGMAR1MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL7095248 | 0.74 | SIGMAR1 (1.00) | SIGMAR1MEN1KMT2ACYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629654-B2 | Concentration of chemical species through the use of photosenstive sorbent materials | GENESIS SYSTEMS LLC (US) | 2026-05-19 | — | — | US | claimed |
| EP-4618976-A1 | COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL CONDITIONS | Dri Biosciences Corporation (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2025129263-A1 | TREATMENT OF BREAKTHROUGH CANCER PAIN | InhaleRx Ltd (AU) | 2025-06-26 | — | — | WO | claimed |
| CN-120192766-A | BTCP-Ac@Eu-MOF double-fluorescence-emission fluorescent probe and preparation method and application thereof | 南京黄教授食品科技有限公司 | 2025-06-24 | — | — | CN | claimed |
| US-20250197653-A1 | MODULATING OBJECT SIGNATURES THROUGH THE USE OF PHOTOSENSTIVE SORBENT COATINGS | GENESIS SYSTEMS LLC | 2025-06-19 | — | — | US | claimed |
| US-20250196095-A1 | CONCENTRATION OF CHEMICAL SPECIES THROUGH THE USE OF PHOTOSENSTIVE SORBENT MATERIALS | GENESIS SYSTEMS LLC | 2025-06-19 | — | — | US | claimed |
| US-20240398978-A1 | Compositions and Methods for Treating Dopamine Disorders | METAQOR LLC (US) | 2024-12-05 | — | — | US | claimed |
| EP-3386493-B1 | DBH INHIBITORS FOR TREATING OR PREVENTING MEMORY LOSS | UNIV BRANDEIS (US) | 2024-11-20 | — | — | EP | claimed |
| WO-2024160196-A1 | USE OF BENCYCLOQUIDIUM BROMIDE, ISOMER THEREOF AND DERIVATIVE THEREOF IN PREPARATION OF OPHTHALMIC FORMULATION | 北京银谷医药科技有限公司 | 2024-08-08 | — | — | WO | claimed |
| WO-2024107961-A1 | COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL CONDITIONS | DRI BIOSCIENCES CORPORATION (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2024074850-A1 | A TREATMENT FOR MENTAL DISORDERS | ReWire Therapeutics Limited (GB) | 2024-04-11 | — | — | WO | claimed |
| CN-103000810-A | Photodiode | SAMSUNG ELECTRONICS CO LTD | 2013-03-27 | — | — | CN | claimed |
| US-20260137691-A1 | WB3 FOR ANESTHESIA AND TREATING PAIN | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-05-21 | — | — | US | disclosed |
| US-12629654-B2 | Concentration of chemical species through the use of photosenstive sorbent materials | GENESIS SYSTEMS LLC (US) | 2026-05-19 | — | — | US | disclosed |
| CN-122046944-A | Optimal design and thermal error suppression method for liquid cooling bionic flow channel of electric spindle of numerical control machine tool | 宁波大学 | 2026-05-15 | — | — | CN | disclosed |
| US-12624030-B2 | 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof | PRINCIPIA BIOPHARMA INC. (US) | 2026-05-12 | — | — | US | disclosed |
| WO-1997012513-A1 | DOPAMINE TRANSPORTER KNOCKOUT MICE | DUKE UNIVERSITY (US) | 1997-04-10 | — | — | WO | disclosed |
| EP-0751937-A1 | N-(BENZHYDRYLOXYALKYL)-4-(CARBOXY/CARBAMOYL-METHYL)-PIPERIDINE DERIVATIVES AS ANTIDEPRESSANTS | COOPERATION PHARMACEUTIQUE FRANCAISE (FR) | 1997-01-08 | — | — | EP | disclosed |
| WO-1995026336-A1 | N-(BENZHYDRYLOXYALKYL)-4-(CARBOXY/CARBAMOYL-METHYL)-PIPERIDINE DERIVATIVES AS ANTIDEPRESSANTS | COOPERATION PHARMACEUTIQUE FRANCAISE (FR) | 1995-10-05 | — | — | WO | disclosed |
| US-5248686-A | Treatment of nervous depression | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1993-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137691-A1 | WB3 FOR ANESTHESIA AND TREATING PAIN | WNT3, TRPV3, ADRB3 | SIGMAR1 576/4885MEN1 4805/4885KMT2A 4685/4885 |
| US-12629654-B2 | Concentration of chemical species through the use of photosenstive sorbent materials | TRPV4, TRPA1, TRPM4 | SIGMAR1 2143/4885MEN1 2698/4885KMT2A 4756/4885 |
| US-20240398978-A1 | Compositions and Methods for Treating Dopamine Disorders | SLC6A3, SNCA, CLTA | SIGMAR1 182/4885MEN1 4442/4885KMT2A 1493/4885 |
| US-12624030-B2 | 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof | ADRA1D, ADRA2C, P2RY1 | SIGMAR1 126/4885MEN1 1796/4885KMT2A 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.